Discover
FULC
Fulcrum Therapeutics, Inc.
3.64
2 x 2.68
7 x 3.69
bid
ask
-
0.02
0.55%
5 @ 04:19 AM
3.55 -0.09 (2.47%)
| Ytd | -67.82% | |
| 1y | -46.78% |
3.61
day range
3.75
2.83
52 week range
15.74
| Open | 3.69 | Prev Close | 3.66 | Low | 3.61 | High | 3.75 | Mkt Cap | 242.55M |
| Vol | 1.61M | Avg Vol | 2.25M | EPS | -1.15 | P/E | N/A | Forward P/E | -3.84 |
| Beta | 2.23 | Short Ratio | 7.67 | Inst. Own | 89.70% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 04-27 | 50-d Avg | 5.56 | 200-d Avg | 8.46 | 1yr Est | 5.29 |
| Income Statement | |||
| Operating Expenses | 22.19M | ||
| Research and Development Expense | 14.08M | ||
| Selling, General and Administrative Expense | 8.10M | ||
| Operating Income | -22.19M | ||
| Net Income | -18.89M | ||
| Net Income Common Stock | -18.89M | ||
| Net Income Common Stock (USD) | -18.89M | ||
| Consolidated Income | -18.89M | ||
| Earnings per Basic Share | -0.25 | ||
| Earnings per Basic Share (USD) | -0.25 | ||
| Earnings per Diluted Share | -0.25 | ||
| Earning Before Interest & Taxes (EBIT) | -18.89M | ||
| Earning Before Interest & Taxes (USD) | -18.89M | ||
| Weighted Average Shares | 76.22M | ||
| Weighted Average Shares Diluted | 76.22M | ||
| Balance Sheet | |||
| Cash and Equivalents | 51.46M | ||
| Cash and Equivalents (USD) | 51.46M | ||
| Investments | 283.06M | ||
| Investments Current | 283.06M | ||
| Current Assets | 338.67M | ||
| Property, Plant & Equipment Net | 6.35M | ||
| Total Assets | 346.77M | ||
| Debt Current | 2.46M | ||
| Total Debt | 5.87M | ||
| Current Liabilities | 9.86M | ||
| Debt Non-Current | 3.41M | ||
| Total Liabilities | 13.47M | ||
| Accumulated Retained Earnings (Deficit) | -613.17M | ||
| Accumulated Other Comprehensive Income | -513.00K | ||
| Shareholders Equity | 333.30M | ||
| Shareholders Equity (USD) | 333.30M | ||
| Assets Non-Current | 8.10M | ||
| Total Debt (USD) | 5.87M | ||
| Liabilities Non-Current | 3.60M | ||
| Trade and Non-Trade Payables | 2.45M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 338.00K | ||
| Net Cash Flow from Financing | -312.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -147.27M | ||
| Capital Expenditure | -8.00K | ||
| Issuance (Purchase) of Equity Shares | -312.00K | ||
| Net Cash Flow from Investing | -128.21M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -128.20M | ||
| Net Cash Flow from Operations | -18.75M | ||
| Share Based Compensation | 3.86M | ||